AN2 Therapeutics (ANTX) officer sees large option repricing, no share sales
Rhea-AI Filing Summary
AN2 Therapeutics, Inc. reported that officer Joshua M. Eizen had certain stock options repriced on March 19, 2026. He received new options to purchase 92,000 and 50,150 shares of common stock at an exercise price of $3.91 per share, replacing prior options for the same share amounts with higher exercise prices of $17.88 and $14.29.
The footnotes explain that the new exercise price equals the closing market price on the repricing date and that vesting schedules remain as previously set. The filing shows no open-market purchases or sales of common stock, only compensation-related option grants and corresponding cancellations back to the issuer.
Positive
- None.
Negative
- None.
Insights
Officer options were repriced, with no open-market trading.
The filing shows Joshua M. Eizen received two new stock option awards covering 92,000 and 50,150 shares at an exercise price of $3.91, while matching older options at exercise prices of $17.88 and $14.29 were returned to the issuer.
Footnotes state the new strike price equals the closing share price on March 19, 2026 and that vesting schedules (25% cliff then monthly, or straight monthly vesting) are unchanged. A conditional “Premium End Date” could reset the exercise price to the original level if certain events occur before that date.
No common shares were bought or sold on the market, and 0% of the position reflects open-market trading. This is a compensation and incentive structure adjustment rather than a directional bet on the stock, so its informational value for near-term sentiment is limited.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 92,000 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 92,000 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 50,150 | $0.00 | -- |
| Disposition | Stock Option (right to buy) | 50,150 | $0.00 | -- |
Footnotes (1)
- The exercise price of the option is $3.91 per share, representing the closing price of the Issuer's common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the "Premium End Date" (as defined below), the repriced option is exercised or the Reporting Person's services with the Company is terminated. The "Premium End Date" means the earliest of: (i) September 19, 2027, (ii) the date of a change in control or (iii) the Reporting Person's death or disability. The shares subject to the option vest as follows: 25% of the shares shall vest on the anniversary of September 29, 2022, and the remainder of the shares shall vest ratably monthly over the subsequent 36 months, subject to the Reporting Person's continuous service through each applicable vesting date. On March 19, 2026, the board of directors of the Issuer approved the repricing of the option. Except as further described in footnote 1, all other terms of the option remain unchanged. The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary measured from January 1, 2023, subject to the Reporting Person's continuous service through each applicable vesting date.
